Kite Pharma hits its Q1 deadline on filing a BLA for its pioneering CAR-T, posts improved data
With the clock ticking down the final hours of Q1, Kite Pharmaceuticals $KITE has kept its pledge to file an application for its pioneering CAR-T therapy in the first quarter. The move puts Kite one step behind Novartis $NVS, which two days ago announced that it had the FDA’s commitment for a speedy review of its own CAR-T.
The question now is whether the FDA will give the Kite’s application a priority review as well, perhaps lining up back-to-back advisory committee meetings to examine the pros and cons of this new wave of cancer therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.